News & ViewsNewslettersContactBecome a Research Patient
DHRHealth Institute for Research and Development

Clinical Trial

A 36-week, randomized, double-blind, placebo controlled, parallel group trial to assess the efficacy and safety of PXL065 versus placebo in noncirrhotic, biopsy-proven Nonalcoholic Steatohepatitis (NASH) patients

Study Status:

Active, Not Recruiting

Please contact us for more information or to learn if you are eligible to participate.

Study Purpose:

To assess the effect of 3 doses of PXL065 (7.5 mg QD, 15 mg QD and 22.5 mg QD) versus placebo on liver fat content (LFC) in NASH patients after 36 weeks of treatment

Information: 

Principal Investigator
Marcel B. Twahirwa, MD
Sponsor
POXEL S.A.
Type of Trial
Interventional
DHRHealth Institute for Research and Development
5323 S. McColl Rd., Edinburg, TX 78539
(956) 362-2390
© 2022 DHR Health Institute for Research & Development | All Rights Reserved | Terms & Conditions | Site By: KangoMedia
chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram